I dont know what stocks your invested in but PROMSING drug platforms are usually between $500-1.5 billion MC. Failed drugs or companies in early stage clinicals are for the sub-$400M. Upon approval or even a submission of a NDA obviously these numbers go much higher.
As far as the delay in JA. Anavex peer-review papers usually take about 1 year from submission. They just released a PR publication on SIGMAR1 that took longer than that. I think NW Bio is well within the range of the typical process. If the rumor of 60 authors is true, obviously this will take longer. Its my guess its close. But in the scheme of things approval is all that matters. JA has zero bearing on MHRA approval and is not required. Personally, I could care less when its released. The only thing that matters to me is manufacturing an submission of a NDA and NW Bio is moving forward with this process. Seems like MHRA is advising NW Bio to move forward on all fronts for a reason: Approval.
Market Data 
Markets 
AI
